Risk factors for aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis

Pediatric Pulmonology

Volumn 45, Issue 8, 2010, Pages 764-771

  Jubin, Virginie ^a   Ranque, Stéphane ^a,b   Le Bel, Nathalie Stremler ^a   Sarles, Jacques ^a   Dubus, Jean Christophe ^a,b  

^a TIMONE HOSPITAL   (France)

^b CNRS   (France)

Author keywords

Aspergillosis; Aspergillus; Azithromycin; Children; Cystic fibrosis

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DORNASE ALFA; NEOMYCIN; TOBRAMYCIN;

ADOLESCENT; ALCALIGENES; ALCALIGENES XYLOSOXYDANS; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALTERNARIA; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; BODY MASS; CANDIDA; CHILD; CLINICAL ARTICLE; FUNGAL COLONIZATION; HUMAN; INFECTION RISK; LEUKOCYTE ACTIVATION; LONG TERM CARE; LUNG FIBROSIS; MEDICAL RECORD REVIEW; NEUTROPHIL CHEMOTAXIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; SCHOOL CHILD; SENSITIZATION; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

ADOLESCENT; ALTERNARIA; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS; AZITHROMYCIN; BODY MASS INDEX; CANDIDA; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; FRANCE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN E; INFANT; MALE; NEUTROPHIL ACTIVATION; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77956111173     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21240     Document Type: Article

References (40)

1. Sharma OP, Chwogule R. Many faces of pulmonary aspergillosis. Eur Respir J 1998;12:705-715.
2. Bargon J, Dauletbaev N, Kohler B, Wolf M, Posselt HG, Wagner TO. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 1999;93:835-838.
3. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37: S225-S264.
4. Milla CE, Wielinski CL, Regelmann WE. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol 1996;21:6-10.
5. Skov M, McKay K, Koch C, Cooper PJ. Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respir Med 2005;99:887-893. (Pubitemid 40796564)
6. Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994;105:32-36.
7. Skov M, Koch C, Reimert CM, Poulsen LK. Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis. Allergy 2000;55:50-58.
8. Shoseyov D, Brownlee KG, Conway SP, Kerem E. Aspergillus bronchitis in cystic fibrosis. Chest 2006;130:222-226.
9. Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in cystic fibrosis patients. Chest 2009;137:171-176.
10. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009;135:805-826.
11. Mastella G, Rainisio M, Harms HK, Hodson ME, Koch C, Navarro J, Strandvik B, McKenzie SG. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000;16:464-471.
12. el-Dahr JM, Fink R, Selden R, Arruda LK, Platts-Mills TA, Heymann PW. Development of immune responses to Aspergillus at an early age in children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:1513-1518.
13. Kraemer R, Delosea N, Ballinari P, Gallati S, Crameri R. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:1211-1220. (Pubitemid 44924822)
14. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999;116: 639-646.
15. Ritz N, Ammann RA, Casaulta Aebischer C, Schoeni-Affolter F, Schoeni MH. Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. Eur J Pediatr 2005;164:577-582.
16. Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, Mastella G, Navarro J, Strandvik B, McKenzie S. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001;31: 1-12.
17. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008;178:814-821.
18. Amitani R, Murayama T, Nawada R, Lee WJ, Niimi A, Suzuki K, Tanaka E, Kuze F. Aspergillus culture filtrates and sputum sols from patients with pulmonary aspergillosis cause damage to human respiratory ciliated epithelium in vitro. Eur Respir J 1995;8:1681-1687.
19. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-1196.
20. Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J 2004;24:834-838.
21. Feldmesser M. Role of neutrophils in invasive aspergillosis. Infect Immun 2006;74:6514-6516.
22. Schaffner A, Davis CE, Schaffner T, Markert M, Douglas H, Braude AI. In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest 1986;78:511-524.
23. Mircescu MM, Lipuma L, van Rooijen N, Pamer EG, Hohl TM. Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection. J Infect Dis 2009;200:647-656.
24. Park SJ, Mehrad B. Innate immunity to Aspergillus species. Clin Microbiol Rev 2009;22:535-551.
25. Bonnett CR, Cornish EJ, Harmsen AG, Burritt JB. Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus Conidia. Infect Immun 2006;74:6528-6539.
26. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004;117: 5S-11S.
27. Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda K, Hershenson MB, Standiford TJ. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004;170:1331-1339. (Pubitemid 39657198)
28. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006;174:566-570.
29. Feanny S, Forsyth S, Corey M, Levison H, Zimmerman B. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a secretory immune response to a colonizing organism. Ann Allergy 1988;60:64-68.
30. Knutsen AP, Bellone C, Kauffman H. Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis. J Cyst Fibros 2002;1:76-89.
31. Knutsen AP, Kariuki B, Consolino JD, Warrier MR. IL-4 alpha chain receptor (IL-4Ralpha) polymorphisms in allergic bronchopulmonary aspergillosis. Clin Mol Allergy 2006; 4:3.
32. Brouard J, Knauer N, Boelle PY, Corvol H, Henrion-Caude A, Flamant C, Bremont F, Delaisi B, Duhamel JF, Marguet C, Roussey M, Miesch MC, Chadelat K, Boule M, Fauroux B, Ratjen F, Grasemann H, Clement A. Influence of interleukin-10 on Aspergillus fumigatus infection in patients with cystic fibrosis. J Infect Dis 2005;191:1988-1991.
33. Smith MJ, Morris L, Stead RJ, Hodson ME, Batten JC. Lymphocyte subpopulations and function in cystic fibrosis. Eur J Respir Dis 1987;70:300-308. (Pubitemid 17082234)
34. Montagnoli C, Fallarino F, Gaziano R, Bozza S, Bellocchio S, Zelante T, Kurup WP, Pitzurra L, Puccetti P, Romani L. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol 2006; 176:1712-1723.
35. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, van Koningsbruggen S, Wahn U, Ratjen F. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-725.
36. Shah PL, Scott SF, Knight RA, Hodson ME. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996;9:531-534.
37. Maiz L, Cuevas M, Quirce S, Canon JF, Pacheco A, Sousa A, Escobar H. Serologic IgE immune responses against Aspergillus fumigatus and Candida albicans in patients with cystic fibrosis. Chest 2002;121:782-788.
38. Hemmann S, Blaser K, Crameri R. Allergens of Aspergillus fumigatus and Candida boidinii share IgE-binding epitopes. Am J Respir Crit Care Med 1997;156:1956-1962. (Pubitemid 28011807)
39. Glaser AG, Menz G, Kirsch AI, Zeller S, Crameri R, Rhyner C. Auto- and cross-reactivity to thioredoxin allergens in allergic bronchopulmonary aspergillosis. Allergy 2008;63:1617-1623.
40. Lee TM, Greenberger PA, Oh S, Patterson R, Roberts M, Liotta JL. Allergic bronchopulmonary candidiasis: case report and suggested diagnostic criteria. J Allergy Clin Immunol 1987;80: 816-820.